Physician profile

Diane Crayton

Family · Alameda, CA

NPI 1184748956

$1,024.89

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$352.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alkermes, INC. $615.67 2021-2024 Lybalvi
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $134.78 2021-2023
Otsuka America Pharmaceutical, INC. $94.83 2022-2023 Abilify Maintena, Abilify Asimtufii
Janssen Pharmaceuticals, INC $59.97 2021-2022
Teva Pharmaceuticals USA, INC. $46.36 2021
Sunovion Pharmaceuticals INC. $35.12 2021
Indivior INC. $20.23 2021
Neurocrine Biosciences, INC. $17.93 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Diane Crayton

$1,024.89

in general payments reported 2019-2025

Years
2021-2024
Top company
Alkermes, INC.

https://glasscript.com/doctor/11072021/diane-crayton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.